OrganiGram Holdings (OGI) Stock

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer (“LP”) of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 (“Q4 Fiscal 2024” or “Fiscal 2024”). All financial information in this press release is expressed in Canadian dollars (“$”). Comparable Periods: The Company's results for Q4 Fiscal 2024 and Fiscal 2024 reflect the three-month and 12-month periods ended.

Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call December 18, 2024 8:00 AM ET Company Participants Max Schwartz - Director of IR Beena Goldenberg - CEO Tim Emberg - CCO Greg Guyatt - CFO Conference Call Participants Aaron Grey - Alliance Global Partners Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Yewon Kang - Canaccord Genuity Operator Good morning. My name is Rob, and I will be your conference operator today.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, December 18, 2024 Time: 8:0.

OrganiGram to pay up to C$100 million ($70.7 million) for vape and prerolled cannabis specialist Motif.

Organigram's stock is undervalued, trading at a 22% discount to tangible book value, with strong growth projections and a solid financial outlook. The company has a high cash balance and no debt, bolstered by additional investment from British American Tobacco. Analysts expect revenue and adjusted EBITDA to grow significantly in FY25 and FY26, making the stock a compelling buy.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram's inaugural product powered by FAST™, the Company's groundbreaking nanoemulsion technology and a first-to-market innovation. FAST™ products deliver up to ~50% faster onset and improved bioavailability delivering nearly double the cannabinoids at peak effect compared to traditional ed.

Organigram's stock has surged 22% since my last analysis, outperforming the cannabis market, yet it remains a buy due to its promising chart and valuation. The fiscal Q3 report exceeded expectations with revenue up 25% and adjusted EBITDA turning positive, highlighting significant financial improvement and strong cash reserves. Analysts have raised their projections for FY25 and FY26, expecting higher revenue and adjusted EBITDA, reinforcing the stock's attractive valuation and growth potential.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Second Tra.

Organigram reported improved 3Q 2024 results. The company holds lead position in the Canadian cannabis market and is increasing its international cannabis exports. OGI stock price trades below its NAV per share and is undervalued.